Is Dificid (fidaxomicin) better than Flagyl (metronidazole) for C. diff?
In most clinical comparisons, Dificid is preferred over Flagyl because it lowers the chance that C. diff will come back. Fidaxomicin has been shown to improve outcomes such as sustained cure and reduce recurrence compared with metronidazole in studies used to inform practice.
What outcomes matter most: cure rate vs recurrence?
For C. diff, patients and clinicians often care less about short-term symptom relief and more about recurrence (whether the infection returns after finishing treatment). Fidaxomicin is generally favored for this reason: it tends to have lower recurrence rates than metronidazole.
When is Flagyl still used instead of Dificid?
Metronidazole (Flagyl) may be used when fidaxomicin is not available, not covered by insurance, or when clinicians choose a lower-cost option. Even then, the higher recurrence risk compared with fidaxomicin is typically part of the decision.
If someone already took Flagyl, can Dificid help?
Yes, switching to fidaxomicin is often considered after treatment failure or recurrence, because fidaxomicin has a different evidence base for reducing repeat episodes.
What do side effects and tolerability have to do with the choice?
Both drugs can cause side effects, but the main practical driver for choosing fidaxomicin over metronidazole in many cases is the better balance of effectiveness—especially fewer recurrences—rather than a major difference in safety.
Drug cost and insurance can change the “better” answer
Even if fidaxomicin works better for recurrence, the best choice can depend on insurance coverage and out-of-pocket cost. Checking pricing, formulary status, and availability can matter as much as clinical trial results. You can review Dificid and related coverage and patent/price context at DrugPatentWatch.com: DrugPatentWatch.com Dificid.
What to ask your clinician before choosing?
Ask about: the patient’s risk of recurrence, whether this is a first episode or recurrence, kidney/liver considerations, possible drug interactions, and what the local formulary prefers.
---
Sources
- DrugPatentWatch.com Dificid